Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Avacta Group PLC LONDON andAvacta Appoints Mats Blom to the Board of Directors as Chair of Audit CommitteeAvacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today announced the appointment of the seasoned biotech executive Mr. Mats Blom as a member of its Board of Directors and Chair of the Audit Committee.
- Antengene Corporation LimitedAntengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG-037 Combined with Selinexor in Cancer Gene TherapyAntengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for...
- Accro Bioscience (Suzhou) LimitedAccro Bioscience Announces Inclusion of AC-101 tablets in the NMPA CDE's "Caring Plan-Extension" Pilot Program for Rare Disease Drug DevelopmentOn September 14, 2026 (China Standard Time, UTC+8), Accro Bioscience announced that AC-101 tablets have been included in the Rare Diseases Innovative Drug Development Encouragement Pilot Program (the "Caring Plan-Extension", known...
- Whitehawk Therapeutics, Inc.Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026PTK7 Expression Remained Stable Following Standard-of-Care Therapies, Supporting Its Relevance as a Target in Second- or Later-Line EGFR NSCLC Findings Reinforce the Scientific Rationale for HWK-007, Whitehawk's Next-Generation PTK7-Directed ADC Currently in Phase 1 Development...
- THE ROSEN LAW FIRM, P. A.Capricor Deadline: CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud LawsuitRosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the "Class Period"), of the important September 28, 2026 lead...
- Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor HarmNew class action for Regeneron (REGN) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 9/14/2026
- Bronstein, Gewirtz & Grossman LLC Urges Capricor Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmNew class action for Capricor (CAPR) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 9/28/2026
- מועד אחרון לתביעה ייצוגית נגד CAPRICOR: רוזן, יועץ משפטי מוביל למשקיעים, קורא למשקיעי חברת Capricor Therapeutics, Inc. לשכור ייצוג משפטי לקראת מועד אחרון חשוב בתביעה ייצוגית בניירות הערך – CAPRניו יורק, Sept. 13, 2026 -- מדוע: משרד רוזן עורכי דין (Rosen Law Firm), משרד עורכי דין בינלאומי העוסק בזכויות משקיעים, מזכיר לרוכשים את ניירות הערך של Capricor Therapeutics, Inc. (נאסד"ק: CAPR), בין התאריכים 17 בדצמבר 2025 עד 26 ביולי 2026, שני התאריכים כוללים ("תקופת התביעה הייצוגית"), את המועד האחרון החשוב של 28 בספטמבר 2026 להגשת תביעה ייצוגית בניירות ערך.
- CAPRICOR DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAPRWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the “Class Period”), of the important September 28, 2026 lead plaintiff deadline.
- Robbins Geller Rudman & Dowd LLPREGN INVESTOR DEADLINE TOMORROW: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP AnnouncesRobbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) common stock between August 1, 2025 and May 15, 2026, inclusive (the "Class Period"), have until tomorrow, Monday, September...
- International Association for the Study of Lung CancerPhase III TAISHAN-302 Trial Shows Tam-Peli Significantly Improves Survival in Relapsed Small-Cell Lung CancerAnti-B7-H3 antibody-drug conjugate reduced the risk of death by 54% versus topotecan and improved progression-free survival and response rates SEOUL, Republic of Korea, Sept. 13, 2026 -- The phase III TAISHAN-302 trial found that tambotatug pelitecan (Tam-Peli, YL201), a...
- International Association for the Study of Lung CancerPhase III ARTEMIS-008 Trial Shows Risvutatug Rezetecan Significantly Improves Overall Survival in Relapsed Small-Cell Lung CancerB7-H3-directed antibody-drug conjugate reduced the risk of death by 54% compared with topotecan and improved progression-free survival and response rates — Results from the randomized Phase III ARTEMIS-008 trial show that risvutatug...